Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products …
Biotechnology
IE, Dublin [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 2.47 | 3.20 | 3.12 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 82.74 | -0.99 | -5.71 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -8.20 | 7.47 | 8.14 | |
| Cash | -16.89 | 4.44 | 5.34 | |
| Capex | 42.76 | -0.05 | -0.09 | |
| Free Cash Flow | -85.15 | 0.08 | 0.51 | |
| Revenue | -8.78 | 2.09 | 2.29 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -1.54 | 0.83 | 0.84 | |
| Operating Margin | 7.39 | 0.12 | 0.12 | |
| ROA | -17.25 | 0.02 | 0.02 | |
| ROE | -16.69 | 0.03 | 0.04 | |
| ROIC | -8.73 | 0.02 | 0.03 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of ALKS is permitted for members.
5
Growth
The "Growth Entry" for the Focus of ALKS is permitted for members.
6
Leverage & Liquidity